Business Club News, December 17th “The international pharmaceutical industry is undergoing major changes and major adjustments. The shift of R&D outsourcing and production to emerging markets has become a trend. The contradiction between R&D investment and output is becoming more and more severe, and the pharmaceutical industry is developing more and more. Relying on foreign technology, China is viewed as a market.†At the National Pharmaceutical Fair on December 9th, Yu Xiong, the deputy head of the China Pharmaceutical Industry Research Institute, was in the theme report “Analysis of Drug R&D and Hot Spot Variety in the Next Three Yearsâ€. The current international pharmaceutical market is summarized.
Yu Xiong believes that large international corporations are accelerating the strategic layout of globalization, expanding the scale of business development, and accelerating the penetration into emerging markets, especially the Chinese market. These factors make China usher in the best time for drug innovation; Chinese pharmaceutical companies The development model should also be changed along with it, and the product is the most fundamental part of China's pharmaceutical industry that should respond to this change and adapt to the development of the industry.
In the report, Yu Xiong analyzed the current situation of large multinational pharmaceutical companies facing the environment and development, analyzed the key areas of foreign drug research, and under these two major international industrial backgrounds and the current policies and conditions of China's pharmaceutical industry, It focuses on the research and development status and market potential of the seven major disease treatment medicines (as shown below) for pharmaceutical companies in the future, such as how to research and develop and transform, and the key drugs in the international drug market, and the new growth potential with the most market potential. The future development trend and the direction that pharmaceutical companies need to focus on are analyzed and interpreted to help industrial and commercial enterprises improve product screening and risk prevention awareness.
Anti-infective drugs: anti-virus into focus
The market for anti-infective diseases is facing the challenge of growth of resistant bacteria. Many pharmaceutical companies have focused their efforts on the development of anti-drug resistant drugs, and the focus of development has shifted from anti-fungal and anti-bacterial drugs to anti-viral drugs. According to Cygnus' estimation, the global anti- infection market will reach 94.1 billion U.S. dollars in 2012, with an average compound annual growth rate of 5.2%.
At present, antibacterial drugs have reached a high degree of saturation and a low growth rate; penicillins and cephalosporins are most widely used, followed by quinolones and macrolides. However, due to the short life cycle of antibacterial drugs, it is gradually losing its appeal to large companies. Market opportunities lie in the treatment of MRSA oral drugs, the treatment of resistant Pseudomonas, and Acinetobacter drugs.
Datamonitor expects the market value of global systemic antifungal drugs to reach US$5.7 billion in 2014; azole drugs will continue to dominate the market for systemic antifungal drugs, and voriconazole and posaconazole will grow rapidly; including caspenevin acetate The global sales of net echinocandins antifungal drugs are expected to quadruple in the next 10 years (from 430 million U.S. dollars in 2004 to nearly 1.2 billion U.S. dollars in 2014).
Benefiting from the H1N1 and HIV drug market, in the global drug market in 2009, the antiviral drug market grew fastest (23%), sales reached $24.8 billion, and accounted for 3.7% of the global drug market.
AIDS medication: Less competition is worth the effort
The use of AIDS drugs as controllable drugs has increased their market volume. There are more than 30 anti-AIDS medications currently approved by the FDA. Chinese raw materials are currently exported very well, but there are not many preparations.
Zidovudine (AZT/ZDV) is the first nucleoside reverse transcriptase inhibitor (AZT/ZDV) approved by the FDA for the treatment of AIDS in the NRTI. The new generation of NRTI is not only rtacaitabine (FTC) but also non-nucleoside reverse transcriptase. Pippivirine, a diaryl pyrimidine (DAPY) compound, is highly active in both primary and variant forms of HIV and is currently the most active NRTI. Phase III clinical trials are currently conducted as an anti-HIV drug.
Anti-tumor drugs: Targeting agents lead high growth
The anti-tumor drug market has strong growth and huge potential. At present, the market share is highly concentrated. Advantageous enterprises and advantageous varieties occupy a relatively large market share. Global market share continues to be concentrated in large-scale enterprises. The domestic market presents a situation in which domestic and foreign competitive companies compete together. .
In terms of development trends, targeted preparations will lead to high growth, indicating the future direction of development of anti-tumor drug research and development. Drugs that have become "bombshells" include Pfizer's sunitinib, Rochelle's joint research and development of erlotinib, Bayer and the United States Onyx's joint development of Sorafenib, etc.; domestic research and development of targeted anti-tumor small molecules Among the innovative drugs, Shenzhen Microchip, Zhejiang Beida, Hengrui, Haosen, Xinchang Pharmaceutical, Shanghai Allis and Hutchison Whampoa have different target targets and indications for targeted anti-cancer drugs in the clinical stage or clinical Application stage.
The market for chemotherapeutic drugs is fiercely competitive, with most of the market shares dominated by leaders such as Sanofi and Eli Lilly; the market for hormone-therapeutic drugs matures, and sales continue to grow as new indications increase, but as a traditional cancer treatment It faces dual competition from traditional drugs such as chemotherapy and biological agents; immunotherapy (biological therapy) is the most promising new method today, and monoclonal antibody therapy for cancer is a very popular research recently.
Cardiovascular medication: Compound preparations tend to heat
The global cardiovascular drug market remains very promising. Because of the prevalence and occurrence of cardiovascular diseases, low- and middle-income countries will become important consumer markets for cardiovascular drugs. Currently, there are antihypertensive drugs, lipid-lowering drugs, and blood regulator drugs. Three-point market situation.
In terms of development trends, the research and development of compound drugs has become increasingly hot, and the joint control of antihypertensive therapy and blood lipid compliance has been the direction of cardiovascular drug research. At the same time, the strengthening of research methods for new drug development methods has attracted new targets and mechanisms of action. Lipitor and Polivit continue to lead the world's best-selling drugs, rivaroxaban and dabigatran will become the market's brightest antithrombotic drugs in 2010.
At present, the global cardiovascular drug R&D environment is not optimistic. Facing severe competition in generic drugs, the recent high-profile product “rout†has led many pharmaceutical companies to slow down the pace of research and development of new cardiovascular drugs.
Antidepressants: Dual Drives for Old and New Products
Depression is one of the four major diseases in the world. In 2008, the global sales of antidepressant drugs reached about 19 billion US dollars. It mainly includes monoamine oxidase inhibitors, tricyclic antidepressants, serotonin (5-HT) reuptake inhibitors, dopamine uptake inhibitors, and selective norepinephrine (NA) reuptake inhibitors. At present, the eight global best-selling drugs are fluoxetine, paroxetine, sertraline, fluvoxamine, venlafaxine, mirtazapine, duloxetine, and amitriptyline.
In the future research and development, secondary development has become an important means for many pharmaceutical companies, such as chiral conversion (S-citalopram), new dosage forms (long-acting controlled-release fluoxetine, oral disintegrating tablets of mirtazapine), etc. In addition, new mechanisms of action are also the focus of attention, such as the dual mechanism (5-HT 1A receptor agonist and 5-HT 2A receptor blocker nicarbobyl), and substance P blockers (Aprepitant from Merck). Natural medicines, etc.
diabetes Medication: New Drug Delivery Paths Are Available
The number of patients with diabetes worldwide has reached 136 million. By 2025, the global population of diabetics will reach 300 million. In the pharmaceutical market in the next few years, insulin preparations and thiazolidinedione hypoglycemic drugs are still among the top companies in the world's diabetes drug market due to their superior efficacy and appropriate pricing.
Non-injected insulin is expected to replace traditional injectables, such as Humalog, a fast-acting insulin dry powder inhaler, Exubera, an inhaled human insulin to be completed in phase III, and Generox's oral insulin.
In addition, diabetes treatment devices have developed into new hotspots, such as artificial pancreas that can control postprandial hyperglycemia, digital smart insulin pens, implantable intestines, insulin film pumps, and implantable electric pulse stimulation therapeutic instruments.
Anti-asthma drugs: Leukotriene receptor antagonists have broad prospects
The incidence of asthma in China is 1%, and the incidence of children is 3%. Under the current medical conditions, the purpose of curing asthma is still not achieved, and only the development of the disease can be controlled. Because the inhalant can reach the lungs, the medicine can be distributed evenly and quickly, and it can avoid the damage to the gastrointestinal tract and reduce the adverse reactions. It plays a decisive role in relieving the asthma attack.
Among the major classes of beta-agonists, glucocorticoids, leukotriene receptor antagonists, antiallergic agents, theophyllines, and anticholinergics, leukotriene receptor antagonists have broad prospects. Special, Proust, montelukast and other products.
Yu Xiong believes that large international corporations are accelerating the strategic layout of globalization, expanding the scale of business development, and accelerating the penetration into emerging markets, especially the Chinese market. These factors make China usher in the best time for drug innovation; Chinese pharmaceutical companies The development model should also be changed along with it, and the product is the most fundamental part of China's pharmaceutical industry that should respond to this change and adapt to the development of the industry.
In the report, Yu Xiong analyzed the current situation of large multinational pharmaceutical companies facing the environment and development, analyzed the key areas of foreign drug research, and under these two major international industrial backgrounds and the current policies and conditions of China's pharmaceutical industry, It focuses on the research and development status and market potential of the seven major disease treatment medicines (as shown below) for pharmaceutical companies in the future, such as how to research and develop and transform, and the key drugs in the international drug market, and the new growth potential with the most market potential. The future development trend and the direction that pharmaceutical companies need to focus on are analyzed and interpreted to help industrial and commercial enterprises improve product screening and risk prevention awareness.
Anti-infective drugs: anti-virus into focus
The market for anti-infective diseases is facing the challenge of growth of resistant bacteria. Many pharmaceutical companies have focused their efforts on the development of anti-drug resistant drugs, and the focus of development has shifted from anti-fungal and anti-bacterial drugs to anti-viral drugs. According to Cygnus' estimation, the global anti- infection market will reach 94.1 billion U.S. dollars in 2012, with an average compound annual growth rate of 5.2%.
At present, antibacterial drugs have reached a high degree of saturation and a low growth rate; penicillins and cephalosporins are most widely used, followed by quinolones and macrolides. However, due to the short life cycle of antibacterial drugs, it is gradually losing its appeal to large companies. Market opportunities lie in the treatment of MRSA oral drugs, the treatment of resistant Pseudomonas, and Acinetobacter drugs.
Datamonitor expects the market value of global systemic antifungal drugs to reach US$5.7 billion in 2014; azole drugs will continue to dominate the market for systemic antifungal drugs, and voriconazole and posaconazole will grow rapidly; including caspenevin acetate The global sales of net echinocandins antifungal drugs are expected to quadruple in the next 10 years (from 430 million U.S. dollars in 2004 to nearly 1.2 billion U.S. dollars in 2014).
Benefiting from the H1N1 and HIV drug market, in the global drug market in 2009, the antiviral drug market grew fastest (23%), sales reached $24.8 billion, and accounted for 3.7% of the global drug market.
AIDS medication: Less competition is worth the effort
The use of AIDS drugs as controllable drugs has increased their market volume. There are more than 30 anti-AIDS medications currently approved by the FDA. Chinese raw materials are currently exported very well, but there are not many preparations.
Zidovudine (AZT/ZDV) is the first nucleoside reverse transcriptase inhibitor (AZT/ZDV) approved by the FDA for the treatment of AIDS in the NRTI. The new generation of NRTI is not only rtacaitabine (FTC) but also non-nucleoside reverse transcriptase. Pippivirine, a diaryl pyrimidine (DAPY) compound, is highly active in both primary and variant forms of HIV and is currently the most active NRTI. Phase III clinical trials are currently conducted as an anti-HIV drug.
Anti-tumor drugs: Targeting agents lead high growth
The anti-tumor drug market has strong growth and huge potential. At present, the market share is highly concentrated. Advantageous enterprises and advantageous varieties occupy a relatively large market share. Global market share continues to be concentrated in large-scale enterprises. The domestic market presents a situation in which domestic and foreign competitive companies compete together. .
In terms of development trends, targeted preparations will lead to high growth, indicating the future direction of development of anti-tumor drug research and development. Drugs that have become "bombshells" include Pfizer's sunitinib, Rochelle's joint research and development of erlotinib, Bayer and the United States Onyx's joint development of Sorafenib, etc.; domestic research and development of targeted anti-tumor small molecules Among the innovative drugs, Shenzhen Microchip, Zhejiang Beida, Hengrui, Haosen, Xinchang Pharmaceutical, Shanghai Allis and Hutchison Whampoa have different target targets and indications for targeted anti-cancer drugs in the clinical stage or clinical Application stage.
The market for chemotherapeutic drugs is fiercely competitive, with most of the market shares dominated by leaders such as Sanofi and Eli Lilly; the market for hormone-therapeutic drugs matures, and sales continue to grow as new indications increase, but as a traditional cancer treatment It faces dual competition from traditional drugs such as chemotherapy and biological agents; immunotherapy (biological therapy) is the most promising new method today, and monoclonal antibody therapy for cancer is a very popular research recently.
Cardiovascular medication: Compound preparations tend to heat
The global cardiovascular drug market remains very promising. Because of the prevalence and occurrence of cardiovascular diseases, low- and middle-income countries will become important consumer markets for cardiovascular drugs. Currently, there are antihypertensive drugs, lipid-lowering drugs, and blood regulator drugs. Three-point market situation.
In terms of development trends, the research and development of compound drugs has become increasingly hot, and the joint control of antihypertensive therapy and blood lipid compliance has been the direction of cardiovascular drug research. At the same time, the strengthening of research methods for new drug development methods has attracted new targets and mechanisms of action. Lipitor and Polivit continue to lead the world's best-selling drugs, rivaroxaban and dabigatran will become the market's brightest antithrombotic drugs in 2010.
At present, the global cardiovascular drug R&D environment is not optimistic. Facing severe competition in generic drugs, the recent high-profile product “rout†has led many pharmaceutical companies to slow down the pace of research and development of new cardiovascular drugs.
Antidepressants: Dual Drives for Old and New Products
Depression is one of the four major diseases in the world. In 2008, the global sales of antidepressant drugs reached about 19 billion US dollars. It mainly includes monoamine oxidase inhibitors, tricyclic antidepressants, serotonin (5-HT) reuptake inhibitors, dopamine uptake inhibitors, and selective norepinephrine (NA) reuptake inhibitors. At present, the eight global best-selling drugs are fluoxetine, paroxetine, sertraline, fluvoxamine, venlafaxine, mirtazapine, duloxetine, and amitriptyline.
In the future research and development, secondary development has become an important means for many pharmaceutical companies, such as chiral conversion (S-citalopram), new dosage forms (long-acting controlled-release fluoxetine, oral disintegrating tablets of mirtazapine), etc. In addition, new mechanisms of action are also the focus of attention, such as the dual mechanism (5-HT 1A receptor agonist and 5-HT 2A receptor blocker nicarbobyl), and substance P blockers (Aprepitant from Merck). Natural medicines, etc.
diabetes Medication: New Drug Delivery Paths Are Available
The number of patients with diabetes worldwide has reached 136 million. By 2025, the global population of diabetics will reach 300 million. In the pharmaceutical market in the next few years, insulin preparations and thiazolidinedione hypoglycemic drugs are still among the top companies in the world's diabetes drug market due to their superior efficacy and appropriate pricing.
Non-injected insulin is expected to replace traditional injectables, such as Humalog, a fast-acting insulin dry powder inhaler, Exubera, an inhaled human insulin to be completed in phase III, and Generox's oral insulin.
In addition, diabetes treatment devices have developed into new hotspots, such as artificial pancreas that can control postprandial hyperglycemia, digital smart insulin pens, implantable intestines, insulin film pumps, and implantable electric pulse stimulation therapeutic instruments.
Anti-asthma drugs: Leukotriene receptor antagonists have broad prospects
The incidence of asthma in China is 1%, and the incidence of children is 3%. Under the current medical conditions, the purpose of curing asthma is still not achieved, and only the development of the disease can be controlled. Because the inhalant can reach the lungs, the medicine can be distributed evenly and quickly, and it can avoid the damage to the gastrointestinal tract and reduce the adverse reactions. It plays a decisive role in relieving the asthma attack.
Among the major classes of beta-agonists, glucocorticoids, leukotriene receptor antagonists, antiallergic agents, theophyllines, and anticholinergics, leukotriene receptor antagonists have broad prospects. Special, Proust, montelukast and other products.
1. Material: Medical Grade Plastic.
2.Used as stopper Connector for disposable Syringe .
3. Easy to apply and remove.
4. Color in white, blue, and red...
5. Different connector are available.
Luer Lock Stopper, medical connector
Stopper ConnectorUsed for disposable syringe
With slick and intact appearance
Highly sealing and sliding performan
Connector,Luer Lock Connector,Medical Tubing Connectors, Catheter Connector , T tap , push pull valves , Turn valve ,medical tube connectors
Surgical care product spare parts
clamp, Valve, Connector,Luer Lock Connector,Medical Tubing Connectors,Catheter Connector, T tap, push pull valves,Turn valve,medical tube connectors
Huali Technology Co., Ltd , https://www.jlhualitech.com